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doi:10.1016/j.jtcvs.2008.03.033650 The Journal of Thoracic and CardObjectives: We present a systematic overview of the literature on reported cases of
chylous pericardial effusion in adults over the past 10 years, assessing clinical presen-
tation, etiology, diagnosis, and treatment.
Methods: We conducted an evidence-based literature review searching for all reported
adult cases of chylopericardium in the past 10 years (January 1996–December 2006).
Results: A total of 33 reported cases of chylopericardium were identified through
a systematic literature search. There was no gender bias in the incidence of chylous
pericardial effusion. Age at diagnosis varied from 18 to 68 years with a mean6 stan-
dard deviation of 36.78 6 14.71 years. Time from symptom onset to diagnosis was
variable (ranging from acute presentation to several years).The most common re-
ported etiology was idiopathic. The diagnosis was made by pericardiocentesis in all
patients. A search for secondary causes included computed tomography of the chest,
lymphoscintigraphy, and lymphangiography along with radioactive oral 131I-triolein.
Conservative therapy was prescribed in 28 patients and failed in 16, in whom subse-
quent surgery was necessary. Overall, 21 patients underwent various types of surgery.
Thoracic duct ligation with creation of a pericardial window was the most common
surgical procedure.
Conclusion: Chylopericardium is a rare entity. The fluid appearance, triglyceride con-
tent, cytologic characteristics, and negative cultures are crucial to make the correct di-
agnosis. Treatment is dependent on the etiology. Surgical management is the most
successful. Conservative therapy is reserved for patients with idiopathic chylopericar-
dium, those with an untreatable etiology, those considered at high risk for surgical
treatment, or those with a predictably short lifespan.
C
hylopericardium is a rare entity in which chylous fluid containing triglycer-
ides in high concentrations accumulates in the pericardial cavity. It was first
described by Hasebrock in 18881 and subsequently reviewed in 1935,2 with 3
cases of chylopericardium being identified among 100 cases of nontraumatic chylo-
thorax.1 The etiology of chylopericardium includes congenital mediastinal lymphan-
giectasia,3 iatrogenic after cardiac surgery,4-6 gastric signet ring cell carcinoma,7
Gorham syndrome (osteolysis that results from lymphangiomatosis with adjacent
bone resorption),8 malignant tumors (eg, mediastinal tumors including mediastinal
dysgerminomas9), blunt or penetrating trauma, infection, radiation, congenital lym-
phatic anomalies,6 or primary idiopathic.10-15 There is no evidence-based systematic
overview on the topic in the past decade. Diagnosis can be challenging and optimal
treatment of chylopericardium remains controversial.
Methods
A computerized Ovid and MEDLINE database search (from January 1, 1996, until
December 31, 2006) was undertaken to identify English and French articles describ-
ing chylopericardium. Search terms included the following: ‘‘chylopericardium,’’
‘‘chylous pericardial effusion,’’ and the combined term ‘‘chylopericardium andiovascular Surgery c September 2008
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VATS 5 video-assisted thoracoscopic surgery
pericardial effusion’’ without limits. We identified 70 articles
on the basis of a priori inclusion criteria16: 29 were deemed
relevant for inclusion in this study (ie, adult patients . 18
years of age with a confirmed diagnosis of chylous pericar-
dial effusion). A second search using the EMBASE database
(from January 1996 until December 1, 2006) was undertaken
using similar search terms and revealed two additional arti-
cles.17,18 In addition, a qualified librarian independently
completed a MEDLINE, Ovid, and EMBASE search and
identified no new articles. The reference section of all articles
was scanned for further articles and no new cases were iden-
tified beyond the electronic search. All relevant articles were
independently reviewed and analyzed by two of the authors
(F.M. and C.D.). Thirty-three cases were identified from
31 articles. Patient demographics, clinical presentation, diag-
nosis, and treatment were identified for each of the cases
(Table 1).
Statistical Analysis
Means and standard deviations were used for categorical var-
iables (Table 1). A formal Kappa test of heterogeneity was
not performed inasmuch as the articles were from different
continents, spanned a decade, and were sufficiently different
to preclude the necessity of formal Kappa testing.
Results
There was no gender bias in disease occurrence: 16 (48%)
female and 17 (52%) male (Table 1). Age at diagnosis ranged
from 18 to 68 years with a mean 6 standard deviation of
36.78 6 14.71 years. Time from onset of symptoms to diag-
nosis showed wide variation ranging from several years (13
years19 in a patient who was incidentally discovered to
have an enlarged heart and remained asymptomatic and 12
years15 in a patient whose condition also was discovered in-
cidentally and who refused pericardiocentesis) to acute pre-
sentations with tamponade.20,21 The commonest causes of
chylopericardium over the past decade were as follows: idio-
pathic (56%),3,10-15,19,20,22-31 postoperative (9%) (viz, mitral
valve replacement [6%],1,4 coronary artery surgery [3%],5
and orthotopic heart transplantation [3%]6), malignant dis-
ease of the lymphatic system or other mediastinal neoplasms
(6%) including mediastinal lymphangioma (3%)32 and medi-
astinal dysgerminoma (3%),9 signet ring cell carcinoma
(3%),7 Gorham syndrome (3%),8 blunt trauma (3%),28 medi-
astinal lymphangiectasis (3%),3 vein thrombosis (3%),17 en-
dovascular treatment of superior vena cava syndrome (3%),33
and tuberculosis (3%).34 Abnormalities of the lymphatic sys-
tem22 and mediastinal lymphangiectasis3 causing chyloperi-The Journal of Thoracardial effusions were referred to as idiopathic causes. The
commonest presentation for patients with chylopericardium
was dyspnea (64%),* including patients with tamponade
(33%)1,5,6,17,18,21-23,32,37 and patients with chest pain or dis-
comfort (12%).9,9,18,20 Two (6%) patients presented with
syncope,14,23 and chylopericardium was diagnosed later.
Diagnosis is usually established after pericardiocentesis
with meticulous fluid analysis, emphasizing fluid color and
triglyceride content (Table 2). Four patients had low pericar-
dial fluid triglyceride levels4,7,20 (181 mg/dL, 216 mg/dL,
245 mg/dL, and 197 mg/dL) and still had a diagnosis of chy-
lous pericardial effusion. All other patients had a triglyceride
level in the pericardial fluid of more than 500 mg/dL with the
highest being 2546 mg/dL.22 Characteristics of the pericar-
dial fluid analysis are summarized in Table 2. There are no
unique features on echocardiogram, chest x-ray film, or elec-
trocardiogram that could predict the diagnosis of chylous
pericardial effusion.
Treatment
Conservative management was prescribed in 28 (84.84%)
patients and consisted of pericardiocentesis alone
(27%),12,19,20,25,28,29,33 pericardiocentesis followed by me-
dium chain triglycerides diet (6%)23,34 and total parenteral
nutrition (12%),1,6,22,24 pericardiocentesis followed by total
parenteral nutrition and external beam radiation (3%),8 peri-
cardiocentesis only followed by total parenteral nutrition
(6%),5,17 pericardiocentesis followed by vena caval revascu-
larization (3%),33 and diagnostic nontherapeutic pericardio-
centesis followed by total parenteral nutrition (9%),4,9,21
low fat diet (6%),7,18 or medium chain triglyceride diet
(9%).3,14,26 In one patient conservative therapy was not de-
scribed (3%).10
Surgery was performed in 21 patients (57.57%),
consisting of open thoracotomy in 7 patients
(33.33%)9,11,12,15,17,18,21,31 or video-assisted thoracoscopic
surgery (VATS) in 10 patients (47.6%)6,10,13,22,25,28-30,32
with subsequent thoracic duct ligation and creation of a peri-
cardial window. One case (4.7%)19 consisted of thoracotomy
and laparotomy with lymphovenous anastomosis between
the thoracic duct and left renal vein. Another case (4.7%)
consisted of pleuropericardial window and tumor resection.9
There have been 2 case reports of chylopericardium in which
the type of surgery (VATS vs open thoracotomy) was not
defined (10.5%).14,23
Conservative treatment failed in 16 of 28 cases (57.1%).y
Time period from diagnosis to surgical treatment varied from
2 days21 to 4 years28 with a mean of 150 days.
Follow-up was reported in 29 of the cases and ranged from
1 month29 to 108 months3 with a mean of 16 months. Four
* References 1, 5-10, 14, 17-22, 26, 29-33, 35, 36.
yReferences 6, 9, 10, 12, 14, 17-19, 21-23, 25, 27-31.cic and Cardiovascular Surgery c Volume 136, Number 3 651
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Case
report
Year of
publication
Age at
diagnosis/
sex
Symptoms at
presentation Cause
Conservative
treatment
Surgical
treatment Complications
Follow-
up
Yokusoglu
M11
2005 36/M Asymptomatic Idiopathic No Yes: open
thoracotomy
No 3 m
Zisis C21 2005 25/M Tamponade Lymphangiomatous
hamartoma?
Yes: TPN Yes: open
thoracotomy
No 12 m
Pop D32 2005 60/M Tamponade Mediastinal
lymphangioma
No Yes z No 15 m
Cho BC24 2005 43/F Asymptomatic Idiopathic Yes:
pericardiocentesis,
MTC diet, TPN,
pericardiostomy
No No 6 m
Mitsui K22 2005 27/F SOB on exertion Idiopathic Yes:
pericardiocentesis,
MTC diet, TPN
Yes: VATS No 41 m
Nanjo S20 2004 47/M CP, SOB Idiopathic Yes:
pericardiocentesis
No No NA
21/F SOB Idiopathic Yes:
pericardiocentesis,
pericardiostomy
Pitol R1 2004 24/F Tamponade MVR Yes:
pericardiocentesis,
MTC diet, TPN
No No NA
Sasaki A4 2002 49/M Asymptomatic MVR Yes: TPN,
pericardiostomy
No No 3 m
Yoshioka H25 2003 28/M Asymptomatic Idiopathic Yes:
pericardiocentesis
Yes: VATS,
12 years later
Salmonella
pericarditis
12 years
later
11 m
Sleilaty G15 2002 68/F Asymptomatic Idiopathic No Yes: open
thoracotomy
No 12 m
Chen FC26 2003 65/F SOB on exertion Idiopathic Yes: MTC diet No No 3 m:
residual
PE
Mahon NG12 2003 25/M Asymptomatic Idiopathic Yes:
pericardiocentesis
Yes: open
thoracotomy
No 18 m
Swelstad MR8 2003 31/F Tamponade Gorham's
syndrome
Yes:
pericardiocentesis,
TPN, external
beam radiation
No Radiation
pneumonitis
NA
Watanabe S10 2002 30/F Tamponade Idiopathic Yes (NA) Yes: VATS No 6 m
Gelsomino S6 2002 40/F CP, SOB, LLE,
then
tamponade
Orthotopic heart
transplantation
Yes:
pericardiocentesis,
TPN, MTC diet
Yes: VATS No 3 m
Wurnig PN28 2000 18/F NA Trauma Yes:
pericardiocentesis
Yes: VATS No 24 m
42/F NA NA No Yes: VATS 7 m
Sakata S13 2000 20/M Asymptomatic Idiopathic No Yes: VATS No 12 m
Wang CH14 2000 61/M Syncope, SOB,
SOB
on exertion
Idiopathic Yes
pericardiostomy,
MTC diet
Yes No 4 m
Sharpe DA5 1999 63/F Tamponade Coronary artery
Surgery
Yes:
pericardiocentesis,
pericardiostomy,
TPN
No No 18 m
Mogulkoc N7 1999 19/F SOB, fatigue,
dry cough
Signet ring cell
carcinoma
Yes: low fat diet No Death after
3.5 m
Death652 The Journal of Thoracic and Cardiovascular Surgery c September 2008
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Case
report
Year of
publication
Age at
diagnosis/
sex
Symptoms at
presentation Cause
Conservative
treatment
Surgical
treatment Complications
Follow-
up
Andrade
Santiago J9
1998 30/M CP, SOB Mediastinal
dysgerminoma
Yes: TPN Yes: PPW Bleeding and
death after
11 days
death
Chello M18 1998 33/F SOB, CP, LLE Idiopathic
(previous
infective
endocarditis,
heroin
addiction)
Yes: low fat diet Yes: open
thoracotomy
No 3 m
Scholten C19 1998 24/M NA, patient
returned after
13 years with
SOB
Idiopathic Yes:
pericardiocentesis
Yes: T&L No 20 m
Furrer M29 1996 35/M SOB, cough then
tamponade
Idiopathic Yes: pericardiocentesis Yes: VATS No 1 m:
residual
PE
Baratella MC3 1998 26/M Asymptomatic Idiopathic Yes: MTC diet No No 108 m
Chen CM17 2004 39/M SOB on
exertion,
tamponade
Thrombosis in
right IJ and
Left SVC
Yes: pericardiocentesis,
TPN
Yes: open
thoracotomy
No NA
Veroux P33 2002 45/F Tamponade SVC syndrome Yes: pericardiocentesis,
VCR
No No NA
Mehrotra S23 2006 22/M Syncope,
tamponade
Idiopathic Yes: pericardiocentesis,
MTC diet
Yes (NA) No 12 m
Liberman M30 2006 45/M Tamponade Idiopathic Yes: pericardiocentesis Yes: VATS No 48 m
Svedjeholm R31 1997 51 F SOB Idiopathic Yes: pericardiocentesis Yes: open
thoracotomy
No 12 m
Wieshammer
S34
2006 22/M SOB Tuberculosis Yes: pericardiocentesis,
MTC diet
No No 9 m
CP, Chest pain, heaviness, discomfort, or oppression; IJ, internal jugular; LLE, bilateral lower leg edema; m, months, MTC, medium chain triclyceride; MVR,
mitral valve replacement; NA, not available; PE, pericardial effusion; PPW, pleuropericardial window and tumor resection; SOB, shortness of breath; SVC,
superior vena cava; T&L, thoracotomy and laparotomy for lymphovenous anastomosis; TPN, total parenteral nutrition; VCR, vena caval revascularization
with local thrombolytic therapy and placement of self-expanding metallic stent. All patients except for one15 underwent diagnostic pericardiocentesis.
Patients listed in Table 1 as having conservative therapy with pericardiocentesis had either therapeutic or diagnostic tap in the setting of tamponade or
else underwent repetitive pericardiocentesis.papers did not report follow-up.1,17,20,33 A small residual
pericardial effusion was noted in 2 cases at 3 months and 1
month after surgery.26,29 Mortality from chylopericardium
was low (only 2 cases, 6%). One patient died of bleeding
11 days after surgery.7 Reports complicated by death were at-
tributed to signet ring cell carcinoma7 and mediastinal dys-
germinoma.9 Among the 18 cases of idiopathic chylous
effusion, conservative therapy failed in 11 (61%) and surgery
was necessaryz; there were no deaths. Two (11%) patients
were treated surgically13,15 and 5 (27.7%) responded to con-
servative therapy alone.
Discussion
The accumulation of chyle in the pericardial cavity is rare.
Causes are multiple and include trauma, mediastinal neo-
zReferences 10, 12, 14, 18, 19, 22, 23, 25, 29-31.The Journal of Thoplasm, thrombosis of the subclavian vein, tuberculosis, tho-
racic surgery,24 Behc¸et syndrome,35 or Gorham syndrome.
Primary idiopathic chylopericardium is known to be a less
common cause of chylopericardium24 but has been reported
with increasing frequency in the past 10 years. Given that id-
iopathic chylous pericardial effusion is rare, it lends itself to
the bias of reporting and publication.
Idiopathic chylopericardium is a diagnosis of exclusion
and is invoked when no discernible cause is evident. This en-
tity has two possible explanations: (1) the presence of dam-
aged lymphatic vessels with abnormal communication of
the thoracic duct to the pericardial lymphatics resulting in
chylous reflux or (2) elevated pressure in the thoracic duct,
which may occur in lymphangiectasia.24
Symptoms at presentation are not indicative of the
cause of the pericardial effusion. Some patients remain
asymptomatic3,4,11-13;15,24-26 and are noted to have cardio-
megaly on routine chest radiograph. Most of the patientsracic and Cardiovascular Surgery c Volume 136, Number 3 653
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nade1,5,17,21,23,32 receive therapeutic and diagnostic pericar-
diocentesis.
Many diagnostic modalities have been described, includ-
ing (1) observation of Sudan III dye distribution into the peri-
cardial cavity after oral intake of Sudan III dye,20 (2)
lymphangioscintigraphy,14,23 (3) lymphangiography,19 and
(4) evaluation of chest radioactivity after an oral dose of
131I-triolein.20 All of these methods are used to ascertain
the cause of the chylous pericardial effusion. Because of
the paucity of cases, the sensitivity and specificity of each di-
agnostic modality is unknown and likely reflects the expertise
of the local center. Lymphoscintigraphy appears to be the
most commonly used modality. Pericardiocentesis followed
by cytology, chemistry, and culture is necessary to defini-
tively make the diagnosis. Analysis of the fluid usually shows
a whitish or milky aspirate with a high triglyceride and pro-
tein content, a predominance of lymphocytes, and the pres-
ence of fat globules by Sudan III staining. Blood cultures
are universally negative. There have been a few cases4,7,20
in which the triglyceride level was low and the diagnosis of
a chylous pericardial effusion was made. This occurs because
there is no universally accepted triglyceride level that is re-
quired to confirm the diagnosis. There is no doubt in the di-
agnosis if the pericardial fluid analyses meets the criteria
shown in Table 2: a milky yellowish appearance, a triglycer-
ide level greater than 500 mg/dL, a cholesterol/triglyceride
ratio less than 1, and negative cultures with lymphocyte pre-
dominance on cytologic examination (one point). A score of
2 (specificity and sensitivity of 100%) is required for a diag-
nosis of chylopericardium.
Optimal treatment of patients with chylopericardium is
unclear. Conservative therapy in the absence of hemody-
namic compromise is one option.25 Rarely, a single pericar-
diocentesis will prevent recurrence.20 Pericardiocentesis
followed by pericardiostomy,24 a medium chain triglyceride
diet,1,3,26,33 or total parenteral nutrition4,5,8 can be tried, espe-
cially if the patient is reluctant to undergo surgery or has con-
comitant life-limiting disease . Conservative treatment failed
in 57.1% of the cases reported,25 and surgical treatment was
curative in all. One late death resulting from bleeding was de-
scribed. There are no clinical indicators to predict the failure
of conservative therapy. Given the low mortality rate in idio-
pathic chylopericardium, initial treatment should include
TABLE 2. Characteristics of chylous fluid analysis
Fluid appearance Milky yellowish appearance
Triglyceride content .500 mg/dL
Cholesterol/triglyceride ratio ,1.0
Fluid cultures Negative cultures
Fluid cell count Lymphocytic predominance654 The Journal of Thoracic and Cardiovascular Surgery c Seppericardiocentesis with a pericardiostomy tube, along with
medium chain triglyceride diet. Failure of this therapy should
prompt surgical intervention. The average time from the ini-
tiation of conservative therapy to the scheduling of surgical
intervention has been 150 days on average, but the median
was 12 days (ranging from 1 day to 1460 days) as reported
in the literature in the past 10 years. This skewing is the result
of a single case28 in which the time from conservative to sur-
gical treatment period was 4 years (1460 days). We concur
with Wurnig and associates28 and suggest surgical interven-
tion in all patients with hemodynamically significant effu-
sions. In addition, recurrence after pericardiocentesis and
failed conservative treatment should be indications for surgi-
cal management. Given that a continuing leakage of chyle
can lead to serious metabolic, nutritional, and immunologic
abnormalities, an average daily loss of chyle of 500 mL daily
over a 5-day period should be an indication for surgical inter-
vention. Almost all patients who had a recurrent chylous
pericardial effusion in a 3-month period required surgical
treatment. Therefore, recurrence should prompt evaluation
for surgical intervention. Treatment of patients with second-
ary chylopericardium should be directed against the underly-
ing cause. Surgery is indicated early in the course of tumor-
induced chylous pericardial effusion and also after a traumatic
event when the daily loss of chyle exceeds 1500 mL per day
in an adult patient.37 Consideration to the use of radiotherapy
and chemotherapy can be discussed if malignant disease is
present in the absence of hemodynamic instability.
Surgical intervention may include thoracic duct ligation,
which usually leads to collateral circulation regardless of
the level of ligation. After ligation, pressures as high as 50
mm Hg have been recorded in the pericardium. This was sub-
sequently followed by a fall in the blood lipid level (from .
500 mg/dL to 280 mg/dL), gradually returning to normal
within 16 days.38 To ensure the success of the surgical proce-
dure, the thoracic duct should be ligated in the lower part of
the thorax and a pericardial window should be created to al-
low adequate drainage and prevent complications such as
constrictive pericarditis.28 Creation of a pericardial window
without thoracic duct ligation is associated with recurrence
in 50% of the cases, whereas it is rare after ligation39,40 and
mostly occurs if duplication of the thoracic duct is present.41
The specific type of surgical procedure, VATS versus
open thoracotomy, depends on the local expertise. Left or
right thoracotomy may be used. Akamatsu and associates39
prefer left thoracotomy inasmuch as the thoracic duct has
its main course in the left hemithorax, surgical time is shorter,
and the likelihood of injury to the esophagus and descending
aorta are lower. The right-sided approach allows easier ac-
cess to the duct. The duct should be ligated near the dia-
phragm owing to the variation in its anatomy above that
level,28 and mass ligation is recommended because of wide
anatomic variations in that specific area above the dia-
phragm.29 Cases involving identification and clipping oftember 2008
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been used,28 with magnification allowing easier identifica-
tion of mediastinal structures. The VATS procedure is
being used increasingly and is associated with less postoper-
ative pain and pulmonary dysfunction.44
Conclusion
Chylopericardium is a rare entity. Presentation may be acute,
chronic, or even subclinical. Diagnosis always requires peri-
cardiocentesis when the color of the fluid characteristics,
triglyceride content, cytologic examination, and negative cul-
ture suggests the diagnosis. Patients should undergo chest
computed tomography followed by lymphangioscintigra-
phy/lymphangiography to rule out secondary causes. Treat-
ment of the underlying cause should always be the therapy
of choice. Cases of idiopathic chylopericardium have been
reported in which conservative therapy with follow-up may
be successful. Conservative therapy should be performed in
cases of idiopathic chylopericardium or if there is an untreat-
able underlying medical condition that shortens lifespan or
surgical risks are considered too high. Open thoracotomy
or VATS, when available, should be considered when con-
servative measures fail or there are no contraindications to
surgery. Surgery should include thoracic duct mass ligation
above the diaphragm with a pericardial window for subse-
quent drainage and prevention of complications such as con-
strictive pericardial disease.
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